Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1997-4-17
|
| pubmed:abstractText |
A randomized, double-'blind', placebo-controlled trial of weekly Maloprim (dapsone-pyrimethamine, D-P) for malaria prophylaxis was conducted at Magoda village in north-eastern Tanzania. The effect of D-P on the incidence of clinical malaria, Plasmodium falciparum prevalence and density, splenomegaly, and packed cell volume (PCV) was investigated in a cohort of 249 children (126 receiving D-P and 123 receiving placebo) aged 1-9 years. The case definition of clinical malaria (malaria fever) was measured axillary temperature > or = 37.5 degrees C and/or reported fever, and P. falciparum asexual parasitaemia > or = 5000/microL. Children aged 1-4 years given D-P experienced 1.56 episodes of clinical malaria per year, whereas children on placebo experienced 2.55 episodes (relative rate [RR] = 0.61, 95% confidence interval [CI] 0.47, 0.80). Thus, D-P protective efficacy against clinical malaria, in this age group, was 39% (95% CI 20%, 53%; P = 0.0002). The annual incidence of clinical malaria among children aged 5-9 years was 0.16 episodes in the D-P group and 0.26 episodes in those receiving placebo (RR = 0.58, 95% CI 0.26, 1.28; P = 0.17). Increased malaria transmission and drug resistance, during the course of the trial, resulted in a reduction in the protective efficacy of D-P. Overall, D-P was able to reduce parasite densities and splenomegaly. D-P prophylaxis also resulted in an increase in PCV but this effect diminished towards the end of the trial. D-P exerted a suppressive effect on asexual parasitaemia throughout the trial.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0035-9203
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
91
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
68-73
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:9093633-Anti-Infective Agents,
pubmed-meshheading:9093633-Child,
pubmed-meshheading:9093633-Child, Preschool,
pubmed-meshheading:9093633-Cohort Studies,
pubmed-meshheading:9093633-Dapsone,
pubmed-meshheading:9093633-Double-Blind Method,
pubmed-meshheading:9093633-Drug Combinations,
pubmed-meshheading:9093633-Drug Resistance,
pubmed-meshheading:9093633-Female,
pubmed-meshheading:9093633-Fever,
pubmed-meshheading:9093633-Follow-Up Studies,
pubmed-meshheading:9093633-Hematocrit,
pubmed-meshheading:9093633-Humans,
pubmed-meshheading:9093633-Infant,
pubmed-meshheading:9093633-Malaria,
pubmed-meshheading:9093633-Male,
pubmed-meshheading:9093633-Parasitemia,
pubmed-meshheading:9093633-Patient Compliance,
pubmed-meshheading:9093633-Prospective Studies,
pubmed-meshheading:9093633-Pyrimethamine,
pubmed-meshheading:9093633-Splenomegaly,
pubmed-meshheading:9093633-Tanzania,
pubmed-meshheading:9093633-Treatment Outcome
|
| pubmed:articleTitle |
Maloprim malaria prophylaxis in children living in a holoendemic village in north-eastern Tanzania.
|
| pubmed:affiliation |
National Institute for Medical Research, Amani Centre, Tanzania.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|